ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,867.60
-0.80%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.31
0.10%
Bitcoin
64,256.88
-0.04%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Denali Therapeutics Inc (DNLI) Quote

Denali Therapeutics Inc

Denali Therapeutics Inc (DNLI)

NASDAQ
15.56
-0.55
(-3.41%)
Closed April 25 4:00PM
Delayed by 15 minutes
15.56
0.00
(0.00%)
After Hours: 7:11PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
15.56
Bid
15.40
Ask
16.78
Volume
944,425
15.47 Day's Range 16.30
15.45 52 Week Range 33.31
Market Cap
2.163B
Previous Close
16.11
Open
16.10
Last Trade
66629
@
15.56
(formt)
Last Trade Time
Financial Volume
$ 14,882,246
VWAP
15.758
Average Volume (3m)
1,279,475
Shares Outstanding
139,160,239
Dividend Yield
-
PE Ratio
-14.89
Earnings Per Share (EPS)
-1.04
Revenue
330.53M
Net Profit
-145.22M

About Denali Therapeutics Inc

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.denalitherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was $16.11. Over the last year, Denali Therapeutics shares have traded in a share price range of $ 15.45 to $ 33.31.

Denali Therapeutics currently has 139,160,239 shares outstanding. The market capitalization of Denali Therapeutics is $2.16 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -14.89.

Denali Therapeutics (DNLI) Options Flow Summary

DNLI Options Flow

Overall Flow

Bearish

Net Premium

-26k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

DNLI Latest News

More News

Form D - Notice of Exempt Offering of Securities

March 01 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 27 2024
Edgar (US Regulatory)

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered...

February 27 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 27 2024
Edgar (US Regulatory)

Denali Therapeutics Announces $500 million Private Placement Equity Financing

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered...

February 27 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 16 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 15 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 15 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 15 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

February 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.82-10.471806674317.3817.5615.47163484616.2352971CS
4-4.49-22.394014962620.0521.0415.47112299117.99259322CS
12-1.04-6.2650602409616.623.5215.47127947518.86691647CS
26-3.3-17.497348886518.8623.8115.45114227519.12597494CS
52-9.58-38.106603023125.1433.3115.4592300621.83928907CS
156-42.03-72.981420385557.5979.715.4572644431.02028206CS
260-8.72-35.914332784224.2893.9412.3964473032.91992534CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
AIREreAlpha Tech Corporation
$ 1.14
(88.74%)
35.42M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
LICNLichen China Limited
$ 0.94
(67.86%)
15.08M
AMSTAmesite Inc
$ 3.31
(65.50%)
70.3M
NCINeo Concept International Group Holdings Ltd
$ 2.33
(-75.47%)
8.33M
GCTKGlucoTrack Inc
$ 0.466
(-38.68%)
1.7M
ISUNiSun Inc
$ 0.0922
(-38.12%)
9.79M
VAXXVaxxinity Inc
$ 0.1326
(-33.70%)
4.95M
EVOEvotec SE
$ 5.2199
(-31.77%)
1.55M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
TSLATesla Inc
$ 162.13
(12.06%)
181.24M
SQQQProShares UltraPro Short QQQ
$ 11.81
(-0.84%)
148.21M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
NKLANikola Corporation
$ 0.6206
(-2.31%)
80.82M

DNLI Discussion

View Posts
conix conix 1 year ago
DNLI on Seeking Alpha

https://seekingalpha.com/article/4570210-denali-need-patient-data-to-justify-that-high-valuation
👍️0
seward seward 2 years ago
Up big, why?
👍️0
seward seward 3 years ago
Up 5 pts AH news or random bid ?
👍️0
seward seward 3 years ago
Add 55.55

Been holding for 100+, flipping small shares
👍️0
seward seward 3 years ago
More flipping.

Filled for one share at 57 this morning. If it hits 62 I can buy coffee.

hans
👍️0
seward seward 3 years ago
Good earnings, flipped some in low 60s
👍️0
seward seward 3 years ago
Adding a little on pullbacks, still looking to hold till it breaks 100 and then sone.
👍️0
seward seward 3 years ago
Best stock I’ve ever seen. Next stop 100 ?
👍️0
seward seward 3 years ago
Up up up. I suppose I should sell it some day. Maybe over 100 ?
👍️0
seward seward 4 years ago
14 may not be in the cards. I may wait for 100.

hans
👍️0
seward seward 5 years ago
Up nice today for no apparent reason.

hans
👍️0
Glider549 Glider549 5 years ago
Interesting .
Stockconsultant daut kom sent me here.
Any debt? Toxic debt?
👍️0
Golden Cross Golden Cross 5 years ago
Back to $14 then do it again!
👍️0
Golden Cross Golden Cross 5 years ago
Looking into if they have a stake in private company Blaze Bioscience and their scorpion venom..GLTA
👍️0
seward seward 5 years ago
In at 14.30, already near 17. Lucky.
👍️0
seward seward 5 years ago
"Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease"

I bought some today

hans
👍️0

Your Recent History

NASDAQ
DNLI
Denali Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved